Biotechnology M&A » By The Online Investor Staff, updated Thu., Apr. 18, 6:00 PM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #42 of 83 |
Slide #42. Cubist Pharmaceuticals — Optimer Pharmaceuticals
Acquirer:
Cubist Pharmaceuticals (CBST)
Acquiree:
Optimer Pharmaceuticals (OPTR)
Details:
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) announced today that it has completed its acquisition of Optimer Pharmaceuticals, Inc. (NASDAQ:,OPTR) for an aggregate upfront cash consideration of approximately $551 million. Optimer stockholders approved the merger agreement at a special meeting of stockholders held on October 23, 2013. Effective today, Optimer common stock will cease to be traded on the NASDAQ.
Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat patients who are hospitalized or are being treated in other acute care settings. Co. has three marketed products: CUBICIN® for the treatment of certain Gram-positive bacteria and for certain bloodstream infections; DIFICID® for the treatment of Clostridium difficile-associated diarrhea (CDAD); and ENTEREG® to accelerate gastrointestinal recovery. Co. has four late-stage product candidates: Tedizolid phosphate and Ceftolozane/tazobactam for treatment of Gram-positive bacterial infections; Surotomycin for CDAD; and Bevenopran for opioid-induced constipation.
Open the CBST Page at The Online Investor »
Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat patients who are hospitalized or are being treated in other acute care settings. Co. has three marketed products: CUBICIN® for the treatment of certain Gram-positive bacteria and for certain bloodstream infections; DIFICID® for the treatment of Clostridium difficile-associated diarrhea (CDAD); and ENTEREG® to accelerate gastrointestinal recovery. Co. has four late-stage product candidates: Tedizolid phosphate and Ceftolozane/tazobactam for treatment of Gram-positive bacterial infections; Surotomycin for CDAD; and Bevenopran for opioid-induced constipation.
Open the OPTR Page at The Online Investor »
|
|||||||||
|
|||||||||
 Free Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
